Skip to main content

Table 2 Univariate and multivariate analysis of risk factors for unfavourable treatment outcomes among MDR-TB patients

From: Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study

Factors Treatment outcomes at the last follow-up Odds ratio (95% CI) Adjusted odds ratio (95% CI) a
Favourable outcomes (n = 20) Unfavourable outcomes (n = 36)
Age (mean±SD) 40.8 ± 16.8 49.1 ± 16.9 0.97 (0.94–1.00)  
Male 16 (80.0) 31 (86.1) 0.65 (0.15–2.74)  
Study sites in
 Western 13 (65.0) 27 (75.0) 1  
 Eastern 7 (35.0) 9 (25.0) 1.62 (0.49–5.30)  
Body mass index (mean±SD) 20.9 ± 2.0 20.0 ± 2.4 1.22 (0.94–1.58) 1.31 (0.99–1.75)
Education
 Primary school or below 9 (45.0) 28 (77.8) 1 1
 Junior high school or above 11 (55.0) 8 (22.2) 4.28 (1.31–13.9) 3.60 (1.04–12.5)
Married 13 (65.0) 17 (47.2) 2.08 (0.67–6.41) 1.66 (0.50–5.55)
Health insurance 19 (95.0) 30 (83.3) 3.80 (0.42–34.1) 4.54 (0.49–42.0)
Haemoptysis 4 (20.0) 11 (30.6) 0.57 (0.15–2.10) 0.59 (0.15–2.29)
Tuberculosis treatment history 6 (30.0) 18 (50.0) 0.43 (0.13–1.36) 0.43 (0.13–1.49)
Pulmonary cavities 12 (60.0) 15 (41.7) 2.10 (0.69–6.39) 1.92 (0.52–7.12)
DST pattern
 MDR 12 (60.0) 18 (50.0) 1 1
 Pre-XDR and XDR 8 (40.0) 18 (50.0) 0.67 (0.22–2.02) 0.87 (0.27–2.84)
Strain family (n = 50)
 Non-Beijing family 2 (10.5) 4 (12.9) 1 1
 Beijing family 17 (89.5) 27 (87.1) 1.26 (0.21–7.64) 1.58 (0.24–10.4)
Treatment regimen
 Non-MDR-TB treatment 13 (65.0) 24 (66.7) 1 1
 MDR-TB treatment 7 (35.0) 12 (33.3) 1.08 (0.34–3.40) 0.52 (0.13–2.10)
MDR-TB diagnosis delay (days)
  ≤ 90.0 13 (65.0) 18 (50.0) 1 1
  > 90.0 7 (35.0) 18 (50.0) 0.54 (0.17–1.66) 0.44 (0.12–1.55)
  1. DNA was failure to extract from six Mycobacterium tuberculosis isolates. Two patients were once reported as treatment success but were lost at the last yearly follow-up, thus excluded from the analysis. MDR Multidrug-resistant, SD Standard deviation, DST Drug susceptibility testing, XDR Extensively drug-resistant
  2. aAdjusted by age, gender and study sites